Revive Therapeutics Ltd. Advances in Gout Treatment with Phase II-A Clinical Study Completion
Revive Therapeutics Ltd., a Canadian health care company specializing in cannabinoid-based products, has recently achieved a significant milestone in its drug development efforts. The company has successfully completed Phase II-A clinical studies for its drug candidate, REV-002, which is being developed for the treatment of acute gout flares. This advancement marks a crucial step forward in the company’s mission to provide innovative solutions in the health care sector.
REV-002, a bucillamine-based formulation, has shown promise in addressing the acute pain and inflammation associated with gout flares. The successful completion of the Phase II-A clinical studies positions Revive Therapeutics to potentially advance to further stages of clinical trials, bringing them closer to bringing a new treatment option to market.
Revive Therapeutics is listed on the Canadian National Stock Exchange, where its shares closed at 0.025 CAD on June 10, 2025. Over the past year, the company’s stock has experienced fluctuations, reaching a 52-week high of 0.035 CAD on June 9, 2025, and a low of 0.005 CAD on March 24, 2025. As of the latest data, the company’s market capitalization stands at 10,464,107 CAD.
The company’s focus on cannabinoid-based products highlights its commitment to exploring alternative therapeutic avenues within the pharmaceutical industry. For more detailed information about Revive Therapeutics and its product offerings, interested parties can visit their website at www.revivethera.com .
As Revive Therapeutics continues to progress in its clinical trials, stakeholders and investors will be closely monitoring the company’s developments, particularly in the context of its potential impact on the treatment of gout and other inflammatory conditions.